Central retinal vein occlusion (CRVO) frequently gives rise to macular edema — accumulation of fluid at the central retina that threatens visual function. This page summarises the evidence-based clinical approach for this specific presentation.
A patient with CRVO is likely to develop macular edema. In eyes with CRVO and macular edema, targeted intravitreal therapy has demonstrated clinically meaningful benefit on both anatomical and functional outcomes.
The first-line treatment for macular edema in this setting involves intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. Multiple agents are available — including both FDA-approved options and one supported by evidence for off-label use.
Reduction or resolution of macular edema, and improvement or stabilization of visual function.
In eyes with CRVO and macular edema, anti-VEGF and intravitreal corticosteroids have demonstrated benefit.
A patient with a CRVO is likely to develop macular edema.
The first line of treatment for associated macular edema is intravitreal anti-vascular endothelial growth factor agents (anti-VEGFs).
Currently, four anti-VEGF agents are used routinely for the treatment of macular edema associated with RVO; three (ranibizumab, aflibercept 2 mg, and faricimab-svoa) are approved by the U.S. Food and Drug Administration (FDA).
Although bevacizumab remains off-label for ophthalmologic conditions, there is evidence demonstrating its efficacy and safety.
DOI: 10.1016/j.ophtha.2024.12.025
View source ↗